Related Experiment Video
Updated: Jul 5, 2026
Analysis of Autophagy in Penicillium chrysogenum by Using Starvation Pads in Combination With Fluorescence Microscopy
Published on: February 1, 2015
Evaluating the Antifungal Potential of Autophagy-Related Protein 4 (ATG4) Inhibitors against Human Fungal Pathogens
Seungmee Jung1, Jongchan Woo1, Hyunjin Cha2
1Department of Molecular Biology, College of Agriculture, Life Sciences, and Natural Resources, University of Wyoming, Laramie WY 82071, USA.
Abstract:
Emerging fungal pathogens pose a significant threat to global public health. Despite the availability of antifungal agents, their clinical efficacy is increasingly challenged by the rise of fungicide-resistant strains. Therefore, identifying novel therapeutic targets and ensuring the safe application of antifungal agents are critical for advancing treatment strategies. Autophagy, a fundamental cellular process that maintains intracellular homeostasis by degrading and recycling dysfunctional proteins and organelles, is implicated in fungal pathogenicity. It indicates that inhibition of autophagy represents a promising approach for antifungal development. In this study, we evaluate the antifungal potential of autophagy inhibitors targeting the Autophagy-related protein 4 (ATG4)-mediated cleavage of Autophagy-related protein 8 (ATG8). Our findings demonstrate that ebselen and its analogs effectively inhibit ATG4 activity in Cryptococcus neoformans, Aspergillus fumigatus, and Aspergillus niger, exhibiting fungicidal activity against Cryptococcus and Candida species. These results provide valuable insights into novel antifungal development strategies, highlighting the therapeutic potential of autophagy inhibitors against diverse pathogenic fungi.
Insights
Novel autophagy inhibitors show promise against drug-resistant fungi. Ebselen and analogs target Autophagy-related protein 4 (ATG4) to inhibit fungal growth, offering new antifungal strategies.
Area of Science:
- Microbiology
- Biochemistry
- Molecular Biology
Background:
- Emerging fungal pathogens present a global health challenge.
- Antifungal resistance compromises existing treatments.
- Autophagy plays a role in fungal pathogenicity.
Purpose of the Study:
- To evaluate autophagy inhibitors as a novel antifungal strategy.
- To investigate the inhibition of Autophagy-related protein 4 (ATG4) activity.
- To assess the efficacy of ebselen and analogs against pathogenic fungi.
Main Methods:
- Studied autophagy inhibition by targeting ATG4-mediated cleavage of Autophagy-related protein 8 (ATG8).
- Tested ebselen and analogs against *Cryptococcus neoformans*, *Aspergillus fumigatus*, *Aspergillus niger*, and *Candida* species.
- Assessed fungicidal activity and ATG4 inhibition.
Main Results:
- Ebselen and analogs demonstrated effective inhibition of ATG4 activity.
- These compounds exhibited fungicidal activity against *Cryptococcus* and *Candida* species.
- Inhibition was observed in *Cryptococcus neoformans*, *Aspergillus fumigatus*, and *Aspergillus niger*.
Conclusions:
- Inhibiting autophagy via ATG4 is a viable antifungal approach.
- Ebselen and its analogs show potential as novel antifungal agents.
- Autophagy inhibitors offer therapeutic possibilities against diverse fungal infections.
